Atinvicitinib (Numelvi)
Atinvicitinib
Intervet South Africa (Pty) Ltd
Registration
- Applicant
- Intervet South Africa (Pty) Ltd
- Registrations
- 4
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Numelvi 4,8 MG tablets EACH TABLET CONTAINS: ATINVICITINIB 4,8 mg | 4,8 mgTablets | 25/0125/13/01 | Registered | Not determined | None |
| Numelvi 7,2 MG tablets EACH TABLET CONTAINS: ATINVICITINIB 7,2 mg | 7,2 mgTablets | 25/0225/13/02 | Registered | Not determined | None |
| Numelvi 21,6 MG tablets EACH TABLET CONTAINS: ATINVICITINIB 21,6 mg | 21,6 mgTablets | 25/0325/13/03 | Registered | Not determined | None |
| Numelvi 31,6 MG tablets EACH TABLET CONTAINS: ATINVICITINIB 31,6 mg | 31,6 mgTablets | 25/0425/13/04 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
1-[(3R,4S)-4-Cyanooxan-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]pyrazole-4-carboxamide
Drag to rotate. Structure from PubChem CID 135138184.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.